ICF Codification QuartzBio

How a Flexible Approach to ICF Codification Reduces Complexity

Biospecimens collected as part of biomarker-informed clinical programs are precious resources for precision medicine research and development (R&D). However, the complexity of tracking and linking informed consent data at the sample and derivative levels limits the use of these biospecimens. In this post, we’ll explore how clinical teams can benefit from QuartzBio’s flexible approach to ICF codification to reduce complexity, gain more value from their stored samples, and help turn their biorepositories into drug development engines. Read More →
4 Strategic Imperatives Biomarker Operations image_2

4 Strategic Imperatives for Clinical and Biomarker Operations 

Keeping track of clinical trial samples across multiple sites and vendors can be manual and tedious (recent post) -- we have demonstrated how virtual Sample Inventory Management can streamline the day-to-day reporting of sample collections, shipments, and discrepancies (webinar series).

Read More →
QuartzBio-22June22-webinar-social-image

Webinar: Monitoring Site and Vendor Performance Metrics Across Studies

Duration: 30 minutes

QuartzBio-22June22-webinar-social-image

Register to Watch On Demand:

Summary

Clinical and translational teams must monitor biomarker samples across global site footprints and dispersed networks of labs and biorepositories.

It's easy to get bogged down by managing the day-to-day requirements of keeping studies on track. With samples as the critical first step toward data generation, modern trials demand a unified approach for evaluating vendor and site performance and their impact on sample operations.

Join our webinar to learn how our team Read More →

Vendor Oversight Use Case Image QuartzBio

Streamlining vendor oversight: Monitoring site-level and laboratory performance across multiple oncology trials

The challenge: Maintaining clinical trial timelines dependent on vendor performance

A global biotechnology company with seven clinical-phase programs approached QuartzBio with a challenge shared by many organizations in the industry -- overall assessment of clinical trial vendors and sites was time-consuming and unreliable, given global site footprints, complex sample lifecycles, and inconsistent naming across sites and vendors.

Tasked with preparing regular executive summaries, the company’s clinical and biomarker operations teams were spending significant time deriving trial-wide key performance indicators (KPIs), lacking visibility into vendor performance – and challenged to translate current experience into future study Read More →